Number of qualified people: CDEC reviewed the uncertainty in the quantity of sufferers with reasonably extreme to critical hemophilia B in Canada qualified for etranacogene dezaparvovec. Medical experts consulted by CADTH indicated that some patients who're labeled as acquiring mild or moderate disease could have a significant bleeding phenotype, which https://donaldf678uus9.wikifrontier.com/user